Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile

Monday, April 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: PRT13722, a first-in-class oral KAT6A degrader, has demonstrated the ability to drive complete tumor regressions in preclinical studies. Additionally, it showcases an improved safety profile concerning hematological effects. This development positions PRT13722 as a promising candidate in cancer therapy.
Price reaction · baseline $4.44 (2026-04-17 close) · hit pre-market · 2 other PRLD headline(s) in the window, move may be shared
day 0 close
+1.6%
day 1
+4.1%
day 3
-0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • PRT13722 shows complete tumor regressions as a monotherapy.
  • The candidate has an improved preclinical hematological safety profile.
  • It is a first-in-class oral KAT6A degrader, indicating innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Monisha Sivakumar, Sarah Pawley, Corey Basch, Jimin Park, Justin Kurian, Anthony Reichelderfer, Yue Zou, Kirsten Gallagher, Miles Cowart, Joy Cote, Alexander Grego, Jessica Burtell, Amy Crossan, Michael Hulse, Anjana Agarwal, Arpita Mondal, Chun Chen, Vijay Devannah, Sina Rezazadeh, Quincy Lewis, Patrick Wen, Ken Ray, Raul Leal, Daniel Porreca, Ganfeng Cao, Neha Bhagwat, Shanthi Ganesan, Stefan Ruepp, Min Wang, Joseph Rager, Koichi Ito, Sandy Geeganage, Andrew Combs, Peggy Scherle, Andrew Buesking, Jack Carter

Frequently Asked Questions

What is PRT13722?

PRT13722 is a first-in-class oral KAT6A degrader candidate.

What results did PRT13722 achieve?

PRT13722 drove complete tumor regressions as a monotherapy.

How does PRT13722's safety profile compare?

It has an improved preclinical hematological safety profile.

What type of therapy is PRT13722 targeting?

PRT13722 is being developed for cancer therapy.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT13722 KAT6A tumor regression hematological safety cancer therapy
Last updated: Apr 20, 2026

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →